New approaches to atherosclerotic cardiovascular disease. the potentialities of torcetrapib.

Article Details

Citation

Copy to clipboard

Perez-Castrillon JL, Duenas-Laita A

New approaches to atherosclerotic cardiovascular disease. the potentialities of torcetrapib.

Recent Pat Cardiovasc Drug Discov. 2006 Jan;1(1):109-14.

PubMed ID

18221079 [ View in PubMed

]

Abstract

Atherosclerosis is the leading cause of death and disability in the developed world. Although the low-density lipoprotein (LDL) cholesterol lowering drugs reduce the mortality and morbidity associated with coronary artery disease, considerable mortality and morbidity remains. Reverse cholesterol transport mediated by high-density lipoproteins (HDL) may provide an independent pathway for lipid removal from atheroma. The current NCEP ATPIII include HDL-cholesterol > or =1.6 mmol/l as a negative risk factor. Torcetrapib is an inhibitor of cholesteryl ester-transfer protein (CETP) that increases high-density lipoprotein (HDL) cholesterol levels. The drug increases HDL-cholesterol and apolipoprotein A-I levels and decreases LDL-cholesterol and apolipoprotein B levels. The effect is showed in monotherapy and when administered in combination with statins. In addition, torcetrapib did not significantly change the serum levels of cholesterol and triglycerides. The raising HDL-cholesterol with torcetrapib could be a new approach to atherosclerotic cardiovascular disease although new trials based on hard clinical end points are necessary.

DrugBank Data that Cites this Article

Drugs

Torcetrapib

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Torcetrapib	Cholesteryl ester transfer protein	Protein	Humans	Yes	Antagonist	Details